SS
RNAC icon

SBI Securities’s Cartesian Therapeutics RNAC Stock Holding History

SBI Securities’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.72K Buy
549
+500
+1,020% +$3.7K ﹤0.01% 2114
2026
Q1 		$301 Hold
49
– – ﹤0.01% 3075
2025
Q4 		$353 Sell
49
-1
-2% -$8 ﹤0.01% 3003
2025
Q3 		$511 Buy
50
+1
+2% +$11 ﹤0.01% 2949
2025
Q2 		$509 Hold
49
– – ﹤0.01% 2960
2025
Q1 		$646 Hold
49
– – ﹤0.01% 2768
2024
Q4 		$878 Buy
+49
New +$992 ﹤0.01% 2673

Other funds holding RNAC

FA
Fedenia Advisers Madison, Wisconsin $421M AUM 96.46% 1-Year Est. Return
TFCP
Twin Focus Capital Partners Boston, Massachusetts $983M AUM 37.07% 1-Year Est. Return
MFS
Miller Financial Services Marshall, Michigan $124M AUM 17.62% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
NSIM
North Star Investment Management Chicago, Illinois $1.84B AUM 28.81% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return
SCM
Sterling Capital Management Charlotte, North Carolina $5.9B AUM 29.63% 1-Year Est. Return

SBI Securities's RNAC Position: Q2 2026 in Review

SBI Securities increased its Cartesian Therapeutics (RNAC) stake by 1,020% in Q2 2026, buying an estimated $3.7K and bringing the position to 549 shares worth $5.72K. The position accounts for ﹤0.01% of the portfolio, ranked #2114.

SBI Securities first reported a position in RNAC in Q4 2024 and has held it in 7 quarters since. 17 funds tracked by Wall St. Rank hold RNAC as of Q2 2026.

  • SBI Securities held 549 shares of Cartesian Therapeutics worth $5.72K as of Q2 2026.
  • SBI Securities bought 500 Cartesian Therapeutics shares in Q2 2026, an estimated $3.7K.
  • Cartesian Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #2114 holding.
  • SBI Securities first reported a position in Cartesian Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 17 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.